Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) EBIT (2023 - 2026)

ArriVent BioPharma has reported EBIT over the past 4 years, most recently at -$46.1 million for Q1 2026.

  • Quarterly results put EBIT at -$46.1 million for Q1 2026, up 30.94% from a year ago — trailing twelve months through Mar 2026 was -$156.9 million (down 11.73% YoY), and the annual figure for FY2025 was -$177.5 million, down 88.25%.
  • EBIT reached -$46.1 million in Q1 2026 per AVBP's latest filing, down from -$38.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$12.2 million in Q1 2023 and bottomed at -$66.8 million in Q1 2025.
  • Median EBIT over the past 4 years was -$24.2 million (2024), compared with a mean of -$30.2 million.
  • The largest annual shift saw EBIT crashed 222.98% in 2025 before it skyrocketed 30.94% in 2026.
  • Over 4 years, EBIT stood at -$23.1 million in 2023, then fell by 2.54% to -$23.7 million in 2024, then crashed by 63.78% to -$38.8 million in 2025, then fell by 18.77% to -$46.1 million in 2026.
  • Business Quant data shows EBIT for AVBP at -$46.1 million in Q1 2026, -$38.8 million in Q4 2025, and -$38.3 million in Q3 2025.